JP Morgan Conference
Jan 6 – Jan 11, 2019
Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four commercialized molecular tests; PancraGen, an integrated molecular pathology platform used for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts and lesions; ThyGeNEXT, a Next Generation Sequencing based mutation profile that identifies mutations from thyroid nodules that are highly indicative of thyroid cancer when traditional cytology is indeterminate; ThyraMIR, a proprietary, miRNA based classifier that assists physicians in identifying those thyroid nodules least likely to be malignant when traditional cytology is indeterminate; and RespriDx, used for distinguishing lesions in the lung that represent new tumors from those caused by metastases from other organs. The Company also has a development portfolio that includes BarreGEN for Barrett’s Esophagus, a test that enables physicians to identify those patients with this common diagnosis that are most likely to progress to esophageal cancer so intervention can be performed.
Interpace Diagnostics was formed in April, 2014 as a Division of PDI, Inc., (created in 1998 as a public company with over 1,000 employees that provided Contract Sales services to pharmaceutical companies.) After the sale of the pharmaceutical contract sales business in December of 2015, Interpace Diagnostics Group became the sole operating company and the name PDI was changed to Interpace Diagnostics Group, Inc. The public company status remained the same (NASDAQ: IDXG). Interpace Diagnostics is an independent molecular diagnostics Company providing services to specialty physicians and medical centers throughout the U.S. and in a limited number of international markets as well.
Interpace Diagnostics Group, Inc.
Morris Corporate Center 1, Building C
300 Interpace Parkway
Parsippany, NJ 07054